文献速递自身炎症与 IgG4 相关病

卡那奴单抗在≤5岁Cryopyrin相关周期性综合征患儿中的长期疗效与安全性

Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger.
PubMed 文献 · Arthritis Rheumatol · 2019-09-09

这项开放标签试验评估卡那奴单抗在≤5岁Cryopyrin相关周期性综合征(CAPS)患儿中的长期疗效、安全性及疫苗接种反应。17例患儿全部获得完全缓解,65%在研究结束时无自身炎症活动,中位CRP随时间下降而SAA无变化;94%可评估疫苗接种后抗体滴度超过保护水平,安全性与此前研究一致。

要点

  • ≤5岁CAPS患儿接受卡那奴单抗后全部获得完全缓解。
  • 研究结束时65%患儿自身炎症活动被评为「无」,中位CRP随时间下降。
  • 94%可评估疫苗接种后抗体滴度超过保护水平,未见对非活疫苗抗体应答的不良影响。

核心结论

  • 卡那奴单抗在≤5岁CAPS患儿中可维持疗效至152周,且似不影响对标准儿童非活疫苗产生抗体。
  • 卡那奴单抗安全性与此前研究一致,支持其在≤5岁CAPS患儿中的长期使用。

研究设计与样本

  • 开放标签试验,纳入年龄≤5岁的CAPS患者,卡那奴单抗2 mg/kg每8周皮下注射。
  • 新生儿起病多系统炎症性疾病(NOMID)患者起始剂量为4 mg/kg。
  • 共纳入17例患者,其中12例(71%)为Muckle-Wells综合征,4例(24%)为NOMID,1例(6%)为家族性寒冷自身炎症综合征。

主要发现

  • 全部17例患者对卡那奴单抗获得完全缓解。
  • 研究结束时65%的患者自身炎症疾病被评估为「无」。
  • 中位CRP水平随时间下降,SAA水平未见明显变化。
  • 在延长期研究中,17次可评估疫苗接种中有16次(94%)接种后抗体滴度升至保护水平以上。

关键数值与推荐

  • 疗效评估采用医生整体疾病活动度评估及血清CRP和SAA水平。
  • 疫苗接种反应通过免疫后4周和8周的接种后抗体滴度评估。

临床怎么用

  • 对于≤5岁CAPS患儿,卡那奴单抗可按2 mg/kg每8周皮下注射给药,NOMID患儿起始剂量为4 mg/kg。
  • 长期使用卡那奴单抗时应监测不良事件,但研究中AE或SAE均未导致治疗中断。
  • 接种标准儿童非活疫苗时无需因卡那奴单抗治疗而担心抗体应答受损。

局限性

  • 为开放标签试验,未设对照。
  • 样本量小(17例),NOMID和家族性寒冷自身炎症综合征患者比例低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess long-term efficacy and safety of canakinumab and the response to vaccination in children ages ≤5 years with cryopyrin-associated periodic syndrome (CAPS). METHODS: CAPS patients (ages ≤5 years) received 2 mg/kg canakinumab subcutaneously every 8 weeks; patients with neonatal-onset multisystem inflammatory disease (NOMID) received a starting dose of 4 mg/kg in this open-label trial. Efficacy was evaluated using physician global assessment of disease activity and serum levels of C-reactive protein (CRP) and amyloid A (SAA). Adverse events (AEs) were recorded. Vaccination response was evaluated using postvaccination antibody titers at 4 and 8 weeks after immunization. RESULTS: Of the 17 patients enrolled, 12 (71%) had Muckle-Wells syndrome, 4 (24%) had NOMID, and 1 (6%) had familial cold autoinflammatory syndrome. All 17 patients had a complete response to canakinumab. Disease activity improved according to the physician global assessment, and for 65% of the patients autoinflammatory disease was characterized as "absent" at the end of the study. Median CRP levels decreased over time. No such change was evident in SAA levels. During the extension study, postvaccination antibody titers increased above protective levels in 16 (94%) of 17 assessable vaccinations. Ten of the patients (59%) had AEs suspected to be related to canakinumab; 8 (47%) experienced at least 1 serious AE (SAE). None of the AEs or SAEs required interruption of canakinumab therapy. CONCLUSION: Our findings indicate that canakinumab effectively maintains efficacy through 152 weeks and appears to have no effect on the ability to produce antibodies against standard childhood non-live vaccines. The safety profile of canakinumab was consistent with previous studies, supporting long-term use of canakinumab for CAPS in children ≤5 years of age.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Brogan PA, Hofer M, Kuemmerle-Deschner JB, et al. Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger. Arthritis Rheumatol. 2019. PMID: 31161734. doi:10.1002/art.41004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。